ClinicalTrials.gg
RecruitingNCT07523971PIVOTUpdated Apr 13, 2026

Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study

An observational study in Dyslipidemias, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by JW Pharmaceutical · Observational

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.

Planned enrollment
6th of 31
10,000 · median 5,000
Started
2025
with 13 others
Observational
31 of 155
7 open now
Primary completion
2026-12
later than 24 of 38 live
Registered
149th of 155
by date
Lead sponsor
6 of 155
JW Pharmaceutical

Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 31 observational ones that give a count, is one of 14 that started in 2025, is one of 31 observational ones, reaches primary completion later than 24 of the 38 other live ones, and was the 149th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Dyslipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Pitavastatin/Ezetimibe tablets (a fixed-dose combination of Pitavastatin and Ezetimibe) in patients with dyslipidemia who also have metabolic syndrome in a real-world clinical setting.

As this is an observational study, participants will be treated according to the investigator's medical judgment and routine clinical practice. The study aims to observe the changes in low-density lipoprotein cholesterol (LDL-C) levels from baseline to 24 weeks and 48 weeks of treatment. Safety will also be assessed by monitoring any adverse events occurring during the 48-week observation period.

Read the detailed description

This is a multi-center, open-label, prospective observational study designed to collect real-world evidence on the efficacy and safety of Pitavastatin/Ezetimibe tablets (2/10 mg and 4/10 mg). The study population consists of adult patients with dyslipidemia who satisfy the criteria for metabolic syndrome.

Key study procedures and objectives include:

Treatment: Participants who are prescribed Pitavastatin/Ezetimibe tablets as part of their routine care will be enrolled. No experimental intervention or forced treatment allocation will be performed.

Efficacy Evaluation: The primary endpoint is the percentage change in LDL-C levels from baseline (Visit 1) to 24 weeks (Visit 2). Secondary endpoints include changes in other lipid parameters (Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, Apo B) and the percentage of patients reaching their target LDL-C levels at 24 and 48 weeks.

Safety Evaluation: All adverse events (AEs) and serious adverse events (SAEs) will be recorded and analyzed to assess the safety profile of the study drug in this specific patient population.

Duration: Each participant will be observed for a total of 48 weeks, with visits occurring at baseline, 24 weeks, and 48 weeks.

The results of this study are expected to provide clinical insights into the long-term management of dyslipidemia in patients with multiple metabolic risk factors using a pitavastatin/ezetimibe combination.

03

Conditions studied

  • Dyslipidemias

Keywords

  • Metabolic Syndrome
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Dyslipidemia Who Also Have Metabolic Syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 years old at the time of written
  2. Subjects diagnosed with dyslipidemia and metabolic syndrome
  3. Subjects who had no treatment history with lipid regulators within 4 weeks prior to Visit1 or who had insufficient therapeutic effects from 8 weeks of treatment with lipid regulators using the same dosage and administration
  4. Subjects who meet the following LDL-C levels according to the classification of cardiovascular disease risk groups* at Visit 1 or who are planned to be treated with Pitavastatin/Ezetimibe Tablets based on the judgment of the investigator
  5. Subjects who voluntarily sign the informed consent form for study participation

Exclusion criteria

Exclusion Criteria:

  1. Individuals for whom Pitavastatin/Ezetimibe Tablets is as specified in the label's Precautions for Use
  2. Individuals who were treated with other products (IP) or investigational devices within 4 weeks prior to participation in the present study or who are expected to have such treatment during the present study
  3. Individuals who are considered to have difficulty participating in the study for other reasons based on the judgment of the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Pitavastatin/Ezetimibe Group

    Patients with dyslipidemia and metabolic syndrome who are prescribed a fixed-dose combination of Pitavastatin and Ezetimibe

06

What researchers measure

Primary outcomes

  1. Percentage change

    Percentage change in LDL-C levels from baseline

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Joung KH, Ku BJ. A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet(R) tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol. Front Endocrinol (Lausanne). 2026 Jul 10;17:1862394. doi: 10.3389/fendo.2026.1862394. eCollection 2026. PubMed 42500128 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect the privacy of study participants and to maintain the confidentiality of proprietary information belonging to the sponsor.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 34 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 90 studies reached it within 40 months; a quarter within 23 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
Apr 13, 2026
StartActual
Jun 25, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523971
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jun 25, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

EUNJU KIM
Contact
kej@jwhealthcare.com
82-2-840-6983

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion